Cyprotex to be bought for £41.7m
Date added:
26/10/2016
MACCLESFIELD-based biotech company Cyprotex is to delist from the AIM market and be acquired by a German drug discovery firm for £41.7m. Evotec will acquire the company's entire share capital at 160p a share. The share price is a premium of 74.9% to the closing price of Cyprotex shares of 91.5p on March 31, the last day of the offer period. The preclinical contract research company, which employs just over 100 staff in the UK, announced that it was undertaking a strategic review in April. Dr Anthony D Baxter, chief executive of ....
Back to all news